A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Ibrutinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics
- 20 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 20 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
- 20 Mar 2018 Status changed from recruiting to active, no longer recruiting.